*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Guangdong True Health Medical Technology Development Co., Ltd.**
**廣東真健康醫療科技開發股份有限公司**
*(a joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock Code: 02697)**

# APPOINTMENT OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

## APPOINTMENT OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE, AND PROCESS AGENT

Reference is hereby made to the announcement dated 2 November 2026 issued by Guangdong True Health Medical Technology Development Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**"), which includes the passing of Ms. Lam Wai Yee Sophie ("**Ms. Lam**"), the joint company secretary of the Company (the "**Joint Company Secretary**"), an authorised representative of the Company (the "**Authorised Representative**") under Rule 3.05 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"), and an authorised person of the Company for accepting service of process and notice in Hong Kong on behalf of the Company (the "**Process Agent**") under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and Rule 19A.13(2) of the Listing Rules.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company hereby announces that Ms. Yip Man Wai ("**Ms. Yip**") has been appointed as a Joint Company Secretary, the Authorised Representative, and the Process Agent of the Company to succeed Ms. Lam, with effect from 3 November 2026. Ms. Yip will jointly perform the duties of company secretary of the Company with Ms. Chen Miaoping ("**Ms. Chen**"), another current Joint Company Secretary.

The biographical details of Ms. Yip and Ms. Chen are set out below respectively:

**Ms. Yip Man Wai (葉文蕙)** is an assistant manager of SWCS Corporate Services Group (Hong Kong) Limited and has over 8 years of experience in the corporate secretarial field. Ms. Yip was admitted as an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom in 2023. She obtained a Bachelor of Business Administration (Honours) degree from Hong Kong Shue Yan University in 2017.

**Ms. Chen Miaoping (陳妙娉)**, aged 47, joined the Group as a Director in March 2022 and was appointed as the chief financial officer of the Company in July 2024. Ms. Chen was appointed as one of the Joint Company Secretaries and redesignated as an executive Director on 20 November 2025, with effect from the 30 June 2026, the listing date of the Company. She is primarily responsible for overall strategic planning, business operations, financial and operational management of the Group.

Ms. Chen has been serving various roles in the Group's subsidiaries, including (i) the executive director, general manager and chief financial officer of True Health (Hainan) Medical Technology Co., Ltd.* (真健康(海南)醫療科技有限公司) since December 2023, December 2023 and July 2024, respectively; (ii) the director, general manager and chief financial officer of True Health (Beijing) Medical Technology Co., Ltd.* (真健康(北京)醫療科技有限公司) since July 2025, July 2025 and July 2024, respectively; (iii) the director, general manager and chief financial officer of True Health Jiesheng (Guangdong Hengqin) Medical Technology Co., Ltd.* (真健康捷盛(廣東橫琴)醫療科技有限公司) since October 2025, October 2025 and December 2024, respectively; (iv) the director of True Health (HK) Medi-Technology Co., Limited (真健康(香港)醫療科技有限公司) since August 2025; (v) the director and general manager of True Health (Guangdong Hengqin) Medical Device Co., Ltd.* (真健康(廣東橫琴)醫療設備有限公司) since October 2025 and October 2025, respectively; (vi) the director, general manager and chief financial officer of True Health (Guangzhou) Medical Device Co., Ltd.* (真健康(廣州)醫療設備有限公司) since May 2026; (vii) the executive director, general manager and chief financial officer of Beijing Zhenyida Medical Technology Co., Ltd.* (北京真易達醫療科技有限公司) since July 2026; (viii) the executive director, general manager and chief financial officer of True Health (Shanghai) Medical Technology Co., Ltd.* (真健康(上海)醫療科技有限公司) since September 2026; and (ix) the executive director and general manager of Beijing True Health Xingan Medical Technology Co., Ltd.* (北京真健康興安醫療科技有限公司) since November 2026.

Furthermore, Ms. Chen previously served as the director, general manager and/or chief financial officer of several former subsidiaries, including (i) the executive director, general manager and chief financial officer of Zhenyida (Beijing) Medical Technology Co., Ltd.* (真易達(北京)醫療科技有限公司) from December 2023, December 2023 and July 2024, respectively, to May 2025; (ii) the executive director and general manager of Zhuhai Jiansheng Medical Technology Co., Ltd.* (珠海健升醫療科技有限公司) from December 2023 to November 2024; (iii) the executive director and general manager of Haikou Weidao Medical Technology Co., Ltd.* (海口微刀醫療科技有限公司) from December 2023 to January 2024; (iv) the executive director and general manager of Zhuhai Yudao Medical Technology Co., Ltd.* (珠海譽刀醫療科技有限公司) from December 2023 to January 2024; (v) the executive director, general manager and chief financial officer of Zhenyida (Huzhou) Medical Technology Co., Ltd.* (真易達(湖州)醫療科技有限公司) from December 2023, December 2023 and July 2024, respectively, to November 2026.

Ms. Chen has over 26 years of experience in pharmaceutical and medical technology industry. Prior to joining the Group, from July 1999 to March 2007, Ms. Chen successively served as the sales representative, regional manager and national supervisory manager of Guangdong

Minglin Pharmaceutical Co., Ltd.* (廣東明林藥業有限公司), a company principally engaged in the wholesale of imported and domestic branded pharmaceutical products, and was responsible for formulating and implementing promotional strategies for national pharmacy chains. From March 2007 to August 2012, she successively served as the sales director and deputy general manager of Hainan Aihe Pharmaceutical Co., Ltd.* (海南艾合藥業有限公司) (formerly known as Hainan Jianyuan Pharmaceutical Co., Ltd.* (海南健元藥業有限公司)), a company principally engaged in the operation of Class III medical device and import and export of drugs, and was responsible for formulating and implementing sales targets of the company. She also served as the executive director and chief executive officer in China Biotech Services Holdings Limited (中國生物科技服務控股有限公司) (formerly known as Rui Kang Pharmaceutical Group Investments Limited (銳康藥業集團投資有限公司) and Longlife Group Holdings Limited (朗力福集團控股有限公司)), a company listed on GEM of the Stock Exchange (Stock Code: 8037) and principally engaged in the provision of medical and health related services from May 2013 to April 2017 and August 2013 to April 2017, respectively. From August 2012 to March 2022, she served as the general manager and sales director of Guangdong Shimalong Pharmaceutical Co., Ltd.* (廣東獅馬龍藥業有限公司) and was responsible for formulating and implementing business strategies.

In January 2012, Ms. Chen obtained a bachelor's degree in pharmacy at China Pharmaceutical University (中國藥科大學) in the People's Republic of China (the "**PRC**"). In November 2016, she obtained a master's degree in pharmaceutical management at Shenyang Pharmaceutical University (瀋陽藥科大學) in the PRC. In November 2005, Ms. Chen obtained the qualification as a pharmacist by Guangdong Provincial Department of Human Resources and Social Security (廣東省人事廳).

**WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

Reference is made to the prospectus of the Company dated 22 June 2026 in relation to, among other things, the appointment of Ms. Chen as a Joint Company Secretary and the waiver granted by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules. The waiver is valid for a period of three years from the date of listing of the Company (i.e. 30 June 2026) (the "**Waiver Period**"), subject to, among other conditions, Ms. Chen being assisted by Ms. Lam throughout the Waiver Period and if Ms. Lam ceases to provide such assistance during the Waiver Period, the Waiver shall be revoked immediately..

Based on the reasons above, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted a new waiver (the "**New Waiver**"), from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules during the remaining Waiver Period (i.e., from 3 November 2026, the date of appointment of Ms. Yip as the Joint Company Secretary, to 5 July 2029) (the "**Remaining Waiver Period**"), on the following conditions:

(i) Ms. Chen must be assisted by Ms. Yip during the Remaining Waiver Period; and

(ii) the New Waiver could be revoked if there is any material breach of the Listing Rules by the Company.

Before the end of the Remaining Waiver Period, the Company must demonstrate and seek the Stock Exchange's confirmation that Ms. Chen, having had the benefit of Ms. Yip's assistance during the Remaining Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary. The Stock Exchange may withdraw or change the New Waiver if the Company's situation changes.

The Board hereby extends its warm welcome to Ms. Yip on her appointment.

By order of the Board
**Guangdong True Health Medical Technology Development Co., Ltd.**
*Chairperson and Executive Director*
**Cheong Hou Iam**

Hong Kong, 12 November 2026

*As at the date of this announcement, the executive Directors are Ms. Cheong Hou Iam (Chairperson), Ms. Chen Miaoping and Ms. Guo Jian and the independent non-executive Directors are Dr. Liu Lianggang, Mr. Ng Kun Seng Chris and Mr. Ma Jianming.*

* *For identification purposes*